Clinical application of 2,5-DI-O-acetyl- -D-gluca ro- (1-4) (6-3)-dilactone (SLA) to the bladder tumor, with special reference to its effect on frequency of tumor recurrences.
D000085:Acetates / Q000627:therapeutic use; D000272:Adipates / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D000085:Acetates; D000272:Adipates; D000970:Antineoplastic Agents; D007783:Lactones